|
|
|
(C) Vancouver
General Hospital.
This monograph may not be reproduced without permission.
For further information, please contact a Pharmacist. |
NAME OF DRUG
ciprofloxacin
CLASSIFICATION
Quinolone Antibiotic
(RESERVED ANTIMICROBIAL DRUG)
ALTERNATE NAME
CIPRO
INDICATIONS
- treatment of infections caused by susceptible strains of micro-organisms
RECONSTITUTION AND STABILITY
- stable at room temperature
- available as premixed bags of 200 mg/100 mL D5W and 400
mg/200 mL D5W
COMPATIBILITY
- compatible with commonly used IV solutions
- compatible via Y site with amikacin, calcium gluconate,
ceftazidime, diphenhydramine, dopamine, gentamicin, lorazepam, metoclopramide,
metronidazole, potassium chloride, ranitidine, tobramycin
- incompatible with other drugs in the same container
ROUTES OF ADMINISTRATION
- IV intermittent
- dilute 200 mg in 100 mL and 400 mg in 250 mL D5W or NS
- volume restricted central line patients may receive more
concentrated solutions up to 4.4 mg/mL (ie. 400 mg in total volume 90 mL –
includes 50 mL minibag + 40 mL drug volume)
- administer dose over 30 minutes in central line patients
and 60 minutes in peripheral line patients
VH & HSC ADMINISTRATION POLICY
A - NOT to be administered by the direct IV route.
DOSAGE
Adults:
- 200-400 mg IV every 12 hours
- maximum recommended dose: 400 mg every 8 hours
NOTE: - dosage adjustments required in patients with renal dysfunction
| CrCl (mL/min) |
Dose |
| £
30 |
200-400 mg Q24H |
| hemodialysis |
200-400 mg once daily, after dialysis |
| peritoneal dialysis |
200-400 mg once daily |
POTENTIAL HAZARDS OF PARENTERAL ADMINISTRATION
- allergic reactions
- injection site pain especially with infusions of shorter duration (30 minutes)
IMPORTANT IMPLICATIONS
- contraindicated in patients who have shown hypersensitivity
to ciprofloxacin or other quinolone antibiotics
- use with caution in prepubertal patients
- adverse reactions may include rash, diarrhea, abdominal pain
- may cause CNS stimulation leading to tremor, restlessness, lightheadedness, confusion
and rarely hallucinations or convulsive seizures; use with caution in patients with
pre-existing neurological disease, patients receivng theophylline preparations or any
condition which may lower the seizure threshold (e.g. alcoholism)
- may increase theophylline serum concentration; if used concomitantly, theophylline
levels should be monitored and dosage adjusted
- may cause prolonged anticoagulation if co-administration
with warfarin; INR should be closely monitored with concomitant use
Rev May 08